KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) Invested Capital (2016 - 2025)

Eli Lilly's Invested Capital history spans 17 years, with the latest figure at $66.3 billion for Q4 2025.

  • For Q4 2025, Invested Capital rose 63.7% year-over-year to $66.3 billion; the TTM value through Dec 2025 reached $66.3 billion, up 63.7%, while the annual FY2025 figure was $66.3 billion, 63.7% up from the prior year.
  • Invested Capital reached $66.3 billion in Q4 2025 per LLY's latest filing, up from $23.8 billion in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $66.3 billion in Q4 2025 to a low of -$4.2 billion in Q1 2022.
  • Average Invested Capital over 5 years is $17.6 billion, with a median of $17.3 billion recorded in 2021.
  • Peak YoY movement for Invested Capital: plummeted 117.57% in 2022, then soared 36652.82% in 2025.
  • A 5-year view of Invested Capital shows it stood at $16.9 billion in 2021, then crashed by 30.23% to $11.8 billion in 2022, then surged by 123.3% to $26.4 billion in 2023, then skyrocketed by 53.75% to $40.5 billion in 2024, then surged by 63.7% to $66.3 billion in 2025.
  • Per Business Quant, the three most recent readings for LLY's Invested Capital are $66.3 billion (Q4 2025), $23.8 billion (Q3 2025), and -$1.8 billion (Q2 2025).